AstraZeneca’s Faslodex approved for new indication in the US
The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Faslodex (fulvestrant), expanding its use with Ibrance (palbociclib) in breast cancer. The combination use is for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer whose cancer has progressed following endocrine therapy.Fulvestrant has been approved in the US since 2002 and in Europe since 2004 as a monotherapy for the treatment of postmenopausal women with HR+ metastatic breast cancer whose cancer has progressed following antioestrogen therapy.
Click on this link for more information.
